Analysts Set Agenus Inc. (NASDAQ:AGEN) PT at $10.00

Shares of Agenus Inc. (NASDAQ:AGEN) have been assigned a consensus recommendation of “Hold” from the six research firms that are presently covering the stock, Marketbeat.com reports. Five analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $10.00.

Separately, HC Wainwright reissued a “neutral” rating on shares of Agenus in a research report on Thursday, December 5th.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Walleye Capital LLC bought a new stake in shares of Agenus during the third quarter valued at approximately $1,003,000. Federated Hermes Inc. purchased a new position in Agenus during the second quarter valued at $1,921,000. Susquehanna Fundamental Investments LLC bought a new stake in shares of Agenus during the 2nd quarter valued at $1,050,000. BNP Paribas Financial Markets grew its position in shares of Agenus by 2,271.5% in the 3rd quarter. BNP Paribas Financial Markets now owns 39,533 shares of the biotechnology company’s stock worth $217,000 after buying an additional 37,866 shares during the period. Finally, Squarepoint Ops LLC bought a new position in shares of Agenus in the 2nd quarter worth about $614,000. Hedge funds and other institutional investors own 61.46% of the company’s stock.

Agenus Price Performance

Shares of Agenus stock opened at $3.12 on Friday. Agenus has a one year low of $2.50 and a one year high of $19.69. The business’s 50 day simple moving average is $3.20 and its two-hundred day simple moving average is $5.62. The stock has a market capitalization of $73.19 million, a P/E ratio of -0.28 and a beta of 1.27.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.